ONETTO NICOLE 4

What Happened

• Nicole Onetto, a director of Bolt Biotherapeutics (BOLT), was granted/acquired a derivative award for 5,000 shares on 2026-06-10. The transaction is reported as an acquisition (code A) at $0.00; the filing lists the instrument as a derivative (typical for stock options or RSUs).
• This was an award/compensation grant (not an open-market purchase or sale). No cash changed hands in this reported event and no immediate sale occurred.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-11 (timely filing).
• Reported amount: 5,000 shares; reported price: $0.00; total reported cash value: $0.
• Vesting: The award vests on the earlier of June 9, 2027 or the day before the next annual meeting, subject to continuous service; the award vests in full upon a change in control (per filing footnote).
• Shares owned after the transaction: not specified in the provided excerpt.
• Filing timeliness: filed within one business day of the transaction (appears timely).

Context

• Derivative award: The filing marks this as a derivative acquisition (commonly a stock option or restricted stock unit). The Form 4 does not specify exercise/strike price or whether the award is an option vs. RSU; those details may appear in the company’s proxy or future filings.
• For retail investors: awards to directors are common as compensation and do not by themselves signal a buy or sell decision. They are informative about executive/director compensation and potential future dilution if exercised or settled.